Industry Research Reports
Home > Reports > Service & Software > Global Neurodegenerative Disease CDMO Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
Global Neurodegenerative Disease CDMO Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
Industry: Service & Software
Published Date: 2025-07-11
Pages: 99 Pages
Report ld: 4788683
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
Neurodegenerative Disease CDMO Market Size(US$)
CAGR 2025-2031
6.9%
Market Size,2031
USD 1,149
Million
Market Snapshot
Market Size in 2025 (Value)
US$ 770 million
Market Forecast in 2031(Value)
US$ 1,149 million
CAGR
6.9%
Years Considered
2020-2031
Base Year
2025
Forecast Period
2025-2031
Source: Secondary research, interviews with experts, and QYResearch analysis
The global Neurodegenerative Disease CDMO market size was US$ 735 million in 2024 and is forecast to a readjusted size of US$ 1149 million by 2031 with a CAGR of 6.9% during the forecast period 2025-2031.
Neurodegenerative disease CDMO is a contract research and development and manufacturing organization that focuses on the field of neurodegenerative diseases and provides pharmaceutical companies and scientific research institutions with a full range of services from drug discovery, preclinical research to commercial production. Its core is to develop innovative therapies for the complex pathologies of diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease (such as abnormal protein aggregation, neuroinflammation, mitochondrial dysfunction, etc.) by integrating professional technology platforms such as neuroscience, protein engineering, cell therapy, and gene therapy. It also relies on a deep understanding of the special requirements of regulatory agencies such as the FDA and EMA (such as biomarker verification and long-term safety assessment) to ensure that research and development and production meet international standards, ultimately accelerating the launch of drugs for the treatment of neurodegenerative diseases.
The North America Neurodegenerative Disease CDMO market size was US$ million in 2024, while Europe was US$ million. The proportion of the North America was % in 2024, while Europe percentage was %, and it is predicted that Europe share will reach % in 2031, trailing a CAGR of % through the analysis period.
The global key players of Neurodegenerative Disease CDMO include AC Immune, Alterity Therapeutics, Biogen, Charles River Laboratories, Coave Therapeutics, Sysmex Corp, Donanemab, Eisai, Fujirebio Holdings, GenSight Biologics, etc. In 2024, the global top five players occupied for a share approximately % in terms of revenue.
In North America, in terms of revenue, in 2024, the top three players hold a share about %, while in Europe, top three players hold a share nearly %.
The global Neurodegenerative Disease CDMO market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2020-2031.
MARKET SEGMENTATION
By Company
- AC Immune
- Alterity Therapeutics
- Biogen
- Charles River Laboratories
- Coave Therapeutics
- Sysmex Corp
- Donanemab
- Eisai
- Fujirebio Holdings
- GenSight Biologics
- Neuropore Therapies
- Nevrargenics
- PPD
- Samsung Biologics
- Sanofi(Vigil Neuroscience)
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- Small Molecule Drug CDMO
- Biopharmaceutical CDMO
- Cell and Gene Therapy (CGT) CDMO
- OtherS
Segment by Application
- Alzheimer's Disease
- Parkinson's Disease
- Huntington's Disease
- Amyotrophic Lateral Sclerosis (ALS)
- Multiple System Atrophy (MSA)
- Progressive Supranuclear Palsy (PSP)
- Others
CHAPTER OUTLINE
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of Neurodegenerative Disease CDMO market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., Biopharmaceutical CDMO in China).
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Parkinson's Disease in India).
Chapter 6: Regional revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
WHY THIS REPORT
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Neurodegenerative Disease CDMO value chain, addressing:
- Market entry risks/opportunities by region
- Product mix optimization based on local practices
- Competitor tactics in fragmented vs. consolidated markets
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Report Overview
1.1 Study Scope
1.2 Market by Type
1.2.1 Global Market Size Growth by Type: 2020 VS 2024 VS 2031
1.2.2 Small Molecule Drug CDMO
1.2.3 Biopharmaceutical CDMO
1.2.4 Cell and Gene Therapy (CGT) CDMO
1.2.5 OtherS
1.3 Market by Application
1.3.1 Global Market Share by Application: 2020 VS 2024 VS 2031
1.3.2 Alzheimer's Disease
1.3.3 Parkinson's Disease
1.3.4 Huntington's Disease
1.3.5 Amyotrophic Lateral Sclerosis (ALS)
1.3.6 Multiple System Atrophy (MSA)
1.3.7 Progressive Supranuclear Palsy (PSP)
1.3.8 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neurodegenerative Disease CDMO Market Perspective (2020-2031)
2.2 Global Market Size by Region: 2020 VS 2024 VS 2031
2.3 Global Neurodegenerative Disease CDMO Revenue Market Share by Region (2020-2025)
2.4 Global Neurodegenerative Disease CDMO Revenue Forecast by Region (2026-2031)
2.5 Major Region and Emerging Market Analysis
2.5.1 North America Neurodegenerative Disease CDMO Market Size and Prospective (2020-2031)
2.5.2 Europe Neurodegenerative Disease CDMO Market Size and Prospective (2020-2031)
2.5.3 China Neurodegenerative Disease CDMO Market Size and Prospective (2020-2031)
2.5.4 Japan Neurodegenerative Disease CDMO Market Size and Prospective (2020-2031)
2.5.5 Southeast Asia Neurodegenerative Disease CDMO Market Size and Prospective (2020-2031)
2.5.6 India Neurodegenerative Disease CDMO Market Size and Prospective (2020-2031)
2.5.7 South America Neurodegenerative Disease CDMO Market Size and Prospective (2020-2031)
2.5.8 Middle East Neurodegenerative Disease CDMO Market Size and Prospective (2020-2031)
3 Breakdown Data by Type
3.1 Global Neurodegenerative Disease CDMO Historic Market Size by Type (2020-2025)
3.2 Global Neurodegenerative Disease CDMO Forecasted Market Size by Type (2026-2031)
3.3 Different Types Neurodegenerative Disease CDMO Representative Players
4 Breakdown Data by Application
4.1 Global Neurodegenerative Disease CDMO Historic Market Size by Application (2020-2025)
4.2 Global Neurodegenerative Disease CDMO Forecasted Market Size by Application (2026-2031)
4.3 New Sources of Growth in Neurodegenerative Disease CDMO Application
5 Competition Landscape by Players
5.1 Global Top Players by Revenue
5.1.1 Global Top Neurodegenerative Disease CDMO Players by Revenue (2020-2025)
5.1.2 Global Neurodegenerative Disease CDMO Revenue Market Share by Players (2020-2025)
5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
5.3 Players Covered: Ranking by Neurodegenerative Disease CDMO Revenue
5.4 Global Neurodegenerative Disease CDMO Market Concentration Analysis
5.4.1 Global Neurodegenerative Disease CDMO Market Concentration Ratio (CR5 and HHI)
5.4.2 Global Top 10 and Top 5 Companies by Neurodegenerative Disease CDMO Revenue in 2024
5.5 Global Key Players of Neurodegenerative Disease CDMO Head office and Area Served
5.6 Global Key Players of Neurodegenerative Disease CDMO, Product and Application
5.7 Global Key Players of Neurodegenerative Disease CDMO, Date of Enter into This Industry
5.8 Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments and Downstream
6.1.1 North America Neurodegenerative Disease CDMO Revenue by Company (2020-2025)
6.1.2 North America Market Size by Type
6.1.2.1 North America Neurodegenerative Disease CDMO Market Size by Type (2020-2025)
6.1.2.2 North America Neurodegenerative Disease CDMO Market Share by Type (2020-2025)
6.1.3 North America Market Size by Application
6.1.3.1 North America Neurodegenerative Disease CDMO Market Size by Application (2020-2025)
6.1.3.2 North America Neurodegenerative Disease CDMO Market Share by Application (2020-2025)
6.1.4 North America Market Trend and Opportunities
6.2 Europe Market: Players, Segments and Downstream
6.2.1 Europe Neurodegenerative Disease CDMO Revenue by Company (2020-2025)
6.2.2 Europe Market Size by Type
6.2.2.1 Europe Neurodegenerative Disease CDMO Market Size by Type (2020-2025)
6.2.2.2 Europe Neurodegenerative Disease CDMO Market Share by Type (2020-2025)
6.2.3 Europe Market Size by Application
6.2.3.1 Europe Neurodegenerative Disease CDMO Market Size by Application (2020-2025)
6.2.3.2 Europe Neurodegenerative Disease CDMO Market Share by Application (2020-2025)
6.2.4 Europe Market Trend and Opportunities
6.3 China Market: Players, Segments and Downstream
6.3.1 China Neurodegenerative Disease CDMO Revenue by Company (2020-2025)
6.3.2 China Market Size by Type
6.3.2.1 China Neurodegenerative Disease CDMO Market Size by Type (2020-2025)
6.3.2.2 China Neurodegenerative Disease CDMO Market Share by Type (2020-2025)
6.3.3 China Market Size by Application
6.3.3.1 China Neurodegenerative Disease CDMO Market Size by Application (2020-2025)
6.3.3.2 China Neurodegenerative Disease CDMO Market Share by Application (2020-2025)
6.3.4 China Market Trend and Opportunities
6.4 Japan Market: Players, Segments and Downstream
6.4.1 Japan Neurodegenerative Disease CDMO Revenue by Company (2020-2025)
6.4.2 Japan Market Size by Type
6.4.2.1 Japan Neurodegenerative Disease CDMO Market Size by Type (2020-2025)
6.4.2.2 Japan Neurodegenerative Disease CDMO Market Share by Type (2020-2025)
6.4.3 Japan Market Size by Application
6.4.3.1 Japan Neurodegenerative Disease CDMO Market Size by Application (2020-2025)
6.4.3.2 Japan Neurodegenerative Disease CDMO Market Share by Application (2020-2025)
6.4.4 Japan Market Trend and Opportunities
6.5 Southeast Asia Market: Players, Segments and Downstream
6.5.1 Southeast Asia Neurodegenerative Disease CDMO Revenue by Company (2020-2025)
6.5.2 Southeast Asia Market Size by Type
6.5.2.1 Southeast Asia Neurodegenerative Disease CDMO Market Size by Type (2020-2025)
6.5.2.2 Southeast Asia Neurodegenerative Disease CDMO Market Share by Type (2020-2025)
6.5.3 Southeast Asia Market Size by Application
6.5.3.1 Southeast Asia Neurodegenerative Disease CDMO Market Size by Application (2020-2025)
6.5.3.2 Southeast Asia Neurodegenerative Disease CDMO Market Share by Application (2020-2025)
6.5.4 Southeast Asia Market Trend and Opportunities
6.6 India Market: Players, Segments and Downstream
6.6.1 India Neurodegenerative Disease CDMO Revenue by Company (2020-2025)
6.6.2 India Market Size by Type
6.6.2.1 India Neurodegenerative Disease CDMO Market Size by Type (2020-2025)
6.6.2.2 India Neurodegenerative Disease CDMO Market Share by Type (2020-2025)
6.6.3 India Market Size by Application
6.6.3.1 India Neurodegenerative Disease CDMO Market Size by Application (2020-2025)
6.6.3.2 India Neurodegenerative Disease CDMO Market Share by Application (2020-2025)
6.6.4 India Market Trend and Opportunities
7 Key Players Profiles
7.1 AC Immune
7.1.1 AC Immune Company Details
7.1.2 AC Immune Business Overview
7.1.3 AC Immune Neurodegenerative Disease CDMO Introduction
7.1.4 AC Immune Revenue in Neurodegenerative Disease CDMO Business (2020-2025)
7.1.5 AC Immune Recent Development
7.2 Alterity Therapeutics
7.2.1 Alterity Therapeutics Company Details
7.2.2 Alterity Therapeutics Business Overview
7.2.3 Alterity Therapeutics Neurodegenerative Disease CDMO Introduction
7.2.4 Alterity Therapeutics Revenue in Neurodegenerative Disease CDMO Business (2020-2025)
7.2.5 Alterity Therapeutics Recent Development
7.3 Biogen
7.3.1 Biogen Company Details
7.3.2 Biogen Business Overview
7.3.3 Biogen Neurodegenerative Disease CDMO Introduction
7.3.4 Biogen Revenue in Neurodegenerative Disease CDMO Business (2020-2025)
7.3.5 Biogen Recent Development
7.4 Charles River Laboratories
7.4.1 Charles River Laboratories Company Details
7.4.2 Charles River Laboratories Business Overview
7.4.3 Charles River Laboratories Neurodegenerative Disease CDMO Introduction
7.4.4 Charles River Laboratories Revenue in Neurodegenerative Disease CDMO Business (2020-2025)
7.4.5 Charles River Laboratories Recent Development
7.5 Coave Therapeutics
7.5.1 Coave Therapeutics Company Details
7.5.2 Coave Therapeutics Business Overview
7.5.3 Coave Therapeutics Neurodegenerative Disease CDMO Introduction
7.5.4 Coave Therapeutics Revenue in Neurodegenerative Disease CDMO Business (2020-2025)
7.5.5 Coave Therapeutics Recent Development
7.6 Sysmex Corp
7.6.1 Sysmex Corp Company Details
7.6.2 Sysmex Corp Business Overview
7.6.3 Sysmex Corp Neurodegenerative Disease CDMO Introduction
7.6.4 Sysmex Corp Revenue in Neurodegenerative Disease CDMO Business (2020-2025)
7.6.5 Sysmex Corp Recent Development
7.7 Donanemab
7.7.1 Donanemab Company Details
7.7.2 Donanemab Business Overview
7.7.3 Donanemab Neurodegenerative Disease CDMO Introduction
7.7.4 Donanemab Revenue in Neurodegenerative Disease CDMO Business (2020-2025)
7.7.5 Donanemab Recent Development
7.8 Eisai
7.8.1 Eisai Company Details
7.8.2 Eisai Business Overview
7.8.3 Eisai Neurodegenerative Disease CDMO Introduction
7.8.4 Eisai Revenue in Neurodegenerative Disease CDMO Business (2020-2025)
7.8.5 Eisai Recent Development
7.9 Fujirebio Holdings
7.9.1 Fujirebio Holdings Company Details
7.9.2 Fujirebio Holdings Business Overview
7.9.3 Fujirebio Holdings Neurodegenerative Disease CDMO Introduction
7.9.4 Fujirebio Holdings Revenue in Neurodegenerative Disease CDMO Business (2020-2025)
7.9.5 Fujirebio Holdings Recent Development
7.10 GenSight Biologics
7.10.1 GenSight Biologics Company Details
7.10.2 GenSight Biologics Business Overview
7.10.3 GenSight Biologics Neurodegenerative Disease CDMO Introduction
7.10.4 GenSight Biologics Revenue in Neurodegenerative Disease CDMO Business (2020-2025)
7.10.5 GenSight Biologics Recent Development
7.11 Neuropore Therapies
7.11.1 Neuropore Therapies Company Details
7.11.2 Neuropore Therapies Business Overview
7.11.3 Neuropore Therapies Neurodegenerative Disease CDMO Introduction
7.11.4 Neuropore Therapies Revenue in Neurodegenerative Disease CDMO Business (2020-2025)
7.11.5 Neuropore Therapies Recent Development
7.12 Nevrargenics
7.12.1 Nevrargenics Company Details
7.12.2 Nevrargenics Business Overview
7.12.3 Nevrargenics Neurodegenerative Disease CDMO Introduction
7.12.4 Nevrargenics Revenue in Neurodegenerative Disease CDMO Business (2020-2025)
7.12.5 Nevrargenics Recent Development
7.13 PPD
7.13.1 PPD Company Details
7.13.2 PPD Business Overview
7.13.3 PPD Neurodegenerative Disease CDMO Introduction
7.13.4 PPD Revenue in Neurodegenerative Disease CDMO Business (2020-2025)
7.13.5 PPD Recent Development
7.14 Samsung Biologics
7.14.1 Samsung Biologics Company Details
7.14.2 Samsung Biologics Business Overview
7.14.3 Samsung Biologics Neurodegenerative Disease CDMO Introduction
7.14.4 Samsung Biologics Revenue in Neurodegenerative Disease CDMO Business (2020-2025)
7.14.5 Samsung Biologics Recent Development
7.15 Sanofi(Vigil Neuroscience)
7.15.1 Sanofi(Vigil Neuroscience) Company Details
7.15.2 Sanofi(Vigil Neuroscience) Business Overview
7.15.3 Sanofi(Vigil Neuroscience) Neurodegenerative Disease CDMO Introduction
7.15.4 Sanofi(Vigil Neuroscience) Revenue in Neurodegenerative Disease CDMO Business (2020-2025)
7.15.5 Sanofi(Vigil Neuroscience) Recent Development
8 Neurodegenerative Disease CDMO Market Dynamics
8.1 Neurodegenerative Disease CDMO Industry Trends
8.2 Neurodegenerative Disease CDMO Market Drivers
8.3 Neurodegenerative Disease CDMO Market Challenges
8.4 Neurodegenerative Disease CDMO Market Restraints
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
TABLE OF FIGURES
List of Tables
Table 1. Global Neurodegenerative Disease CDMO Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global Neurodegenerative Disease CDMO Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Market Neurodegenerative Disease CDMO Market Size (US$ Million) by Region:2020 VS 2024 VS 2031
Table 4. Global Neurodegenerative Disease CDMO Revenue (US$ Million) Market Share by Region (2020-2025)
Table 5. Global Neurodegenerative Disease CDMO Revenue Share by Region (2020-2025)
Table 6. Global Neurodegenerative Disease CDMO Revenue (US$ Million) Forecast by Region (2026-2031)
Table 7. Global Neurodegenerative Disease CDMO Revenue Share Forecast by Region (2026-2031)
Table 8. Global Neurodegenerative Disease CDMO Market Size by Type (2020-2025) & (US$ Million)
Table 9. Global Neurodegenerative Disease CDMO Revenue Market Share by Type (2020-2025)
Table 10. Global Neurodegenerative Disease CDMO Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 11. Global Neurodegenerative Disease CDMO Revenue Market Share by Type (2026-2031)
Table 12. Representative Players of Each Type
Table 13. Global Neurodegenerative Disease CDMO Market Size by Application (2020-2025) & (US$ Million)
Table 14. Global Neurodegenerative Disease CDMO Revenue Market Share by Application (2020-2025)
Table 15. Global Neurodegenerative Disease CDMO Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 16. Global Neurodegenerative Disease CDMO Revenue Market Share by Application (2026-2031)
Table 17. New Sources of Growth in Neurodegenerative Disease CDMO Application
Table 18. Global Neurodegenerative Disease CDMO Revenue by Players (2020-2025) & (US$ Million)
Table 19. Global Neurodegenerative Disease CDMO Market Share by Players (2020-2025)
Table 20. Global Top Neurodegenerative Disease CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Disease CDMO as of 2024)
Table 21. Ranking of Global Top Neurodegenerative Disease CDMO Companies by Revenue (US$ Million) in 2024
Table 22. Global 5 Largest Players Market Share by Neurodegenerative Disease CDMO Revenue (CR5 and HHI) & (2020-2025)
Table 23. Global Key Players of Neurodegenerative Disease CDMO, Headquarters and Area Served
Table 24. Global Key Players of Neurodegenerative Disease CDMO, Product and Application
Table 25. Global Key Players of Neurodegenerative Disease CDMO, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. North America Neurodegenerative Disease CDMO Revenue by Company (2020-2025) & (US$ Million)
Table 28. North America Neurodegenerative Disease CDMO Revenue Market Share by Company (2020-2025)
Table 29. North America Neurodegenerative Disease CDMO Market Size by Type (2020-2025) & (US$ Million)
Table 30. North America Neurodegenerative Disease CDMO Market Size by Application (2020-2025) & (US$ Million)
Table 31. Europe Neurodegenerative Disease CDMO Revenue by Company (2020-2025) & (US$ Million)
Table 32. Europe Neurodegenerative Disease CDMO Revenue Market Share by Company (2020-2025)
Table 33. Europe Neurodegenerative Disease CDMO Market Size by Type (2020-2025) & (US$ Million)
Table 34. Europe Neurodegenerative Disease CDMO Market Size by Application (2020-2025) & (US$ Million)
Table 35. China Neurodegenerative Disease CDMO Revenue by Company (2020-2025) & (US$ Million)
Table 36. China Neurodegenerative Disease CDMO Revenue Market Share by Company (2020-2025)
Table 37. China Neurodegenerative Disease CDMO Market Size by Type (2020-2025) & (US$ Million)
Table 38. China Neurodegenerative Disease CDMO Market Size by Application (2020-2025) & (US$ Million)
Table 39. Japan Neurodegenerative Disease CDMO Revenue by Company (2020-2025) & (US$ Million)
Table 40. Japan Neurodegenerative Disease CDMO Revenue Market Share by Company (2020-2025)
Table 41. Japan Neurodegenerative Disease CDMO Market Size by Type (2020-2025) & (US$ Million)
Table 42. Japan Neurodegenerative Disease CDMO Market Size by Application (2020-2025) & (US$ Million)
Table 43. Southeast Asia Neurodegenerative Disease CDMO Revenue by Company (2020-2025) & (US$ Million)
Table 44. Southeast Asia Neurodegenerative Disease CDMO Revenue Market Share by Company (2020-2025)
Table 45. Southeast Asia Neurodegenerative Disease CDMO Market Size by Type (2020-2025) & (US$ Million)
Table 46. Southeast Asia Neurodegenerative Disease CDMO Market Size by Application (2020-2025) & (US$ Million)
Table 47. India Neurodegenerative Disease CDMO Revenue by Company (2020-2025) & (US$ Million)
Table 48. India Neurodegenerative Disease CDMO Revenue Market Share by Company (2020-2025)
Table 49. India Neurodegenerative Disease CDMO Market Size by Type (2020-2025) & (US$ Million)
Table 50. India Neurodegenerative Disease CDMO Market Size by Application (2020-2025) & (US$ Million)
Table 51. AC Immune Company Details
Table 52. AC Immune Business Overview
Table 53. AC Immune Neurodegenerative Disease CDMO Product
Table 54. AC Immune Revenue in Neurodegenerative Disease CDMO Business (2020-2025) & (US$ Million)
Table 55. AC Immune Recent Development
Table 56. Alterity Therapeutics Company Details
Table 57. Alterity Therapeutics Business Overview
Table 58. Alterity Therapeutics Neurodegenerative Disease CDMO Product
Table 59. Alterity Therapeutics Revenue in Neurodegenerative Disease CDMO Business (2020-2025) & (US$ Million)
Table 60. Alterity Therapeutics Recent Development
Table 61. Biogen Company Details
Table 62. Biogen Business Overview
Table 63. Biogen Neurodegenerative Disease CDMO Product
Table 64. Biogen Revenue in Neurodegenerative Disease CDMO Business (2020-2025) & (US$ Million)
Table 65. Biogen Recent Development
Table 66. Charles River Laboratories Company Details
Table 67. Charles River Laboratories Business Overview
Table 68. Charles River Laboratories Neurodegenerative Disease CDMO Product
Table 69. Charles River Laboratories Revenue in Neurodegenerative Disease CDMO Business (2020-2025) & (US$ Million)
Table 70. Charles River Laboratories Recent Development
Table 71. Coave Therapeutics Company Details
Table 72. Coave Therapeutics Business Overview
Table 73. Coave Therapeutics Neurodegenerative Disease CDMO Product
Table 74. Coave Therapeutics Revenue in Neurodegenerative Disease CDMO Business (2020-2025) & (US$ Million)
Table 75. Coave Therapeutics Recent Development
Table 76. Sysmex Corp Company Details
Table 77. Sysmex Corp Business Overview
Table 78. Sysmex Corp Neurodegenerative Disease CDMO Product
Table 79. Sysmex Corp Revenue in Neurodegenerative Disease CDMO Business (2020-2025) & (US$ Million)
Table 80. Sysmex Corp Recent Development
Table 81. Donanemab Company Details
Table 82. Donanemab Business Overview
Table 83. Donanemab Neurodegenerative Disease CDMO Product
Table 84. Donanemab Revenue in Neurodegenerative Disease CDMO Business (2020-2025) & (US$ Million)
Table 85. Donanemab Recent Development
Table 86. Eisai Company Details
Table 87. Eisai Business Overview
Table 88. Eisai Neurodegenerative Disease CDMO Product
Table 89. Eisai Revenue in Neurodegenerative Disease CDMO Business (2020-2025) & (US$ Million)
Table 90. Eisai Recent Development
Table 91. Fujirebio Holdings Company Details
Table 92. Fujirebio Holdings Business Overview
Table 93. Fujirebio Holdings Neurodegenerative Disease CDMO Product
Table 94. Fujirebio Holdings Revenue in Neurodegenerative Disease CDMO Business (2020-2025) & (US$ Million)
Table 95. Fujirebio Holdings Recent Development
Table 96. GenSight Biologics Company Details
Table 97. GenSight Biologics Business Overview
Table 98. GenSight Biologics Neurodegenerative Disease CDMO Product
Table 99. GenSight Biologics Revenue in Neurodegenerative Disease CDMO Business (2020-2025) & (US$ Million)
Table 100. GenSight Biologics Recent Development
Table 101. Neuropore Therapies Company Details
Table 102. Neuropore Therapies Business Overview
Table 103. Neuropore Therapies Neurodegenerative Disease CDMO Product
Table 104. Neuropore Therapies Revenue in Neurodegenerative Disease CDMO Business (2020-2025) & (US$ Million)
Table 105. Neuropore Therapies Recent Development
Table 106. Nevrargenics Company Details
Table 107. Nevrargenics Business Overview
Table 108. Nevrargenics Neurodegenerative Disease CDMO Product
Table 109. Nevrargenics Revenue in Neurodegenerative Disease CDMO Business (2020-2025) & (US$ Million)
Table 110. Nevrargenics Recent Development
Table 111. PPD Company Details
Table 112. PPD Business Overview
Table 113. PPD Neurodegenerative Disease CDMO Product
Table 114. PPD Revenue in Neurodegenerative Disease CDMO Business (2020-2025) & (US$ Million)
Table 115. PPD Recent Development
Table 116. Samsung Biologics Company Details
Table 117. Samsung Biologics Business Overview
Table 118. Samsung Biologics Neurodegenerative Disease CDMO Product
Table 119. Samsung Biologics Revenue in Neurodegenerative Disease CDMO Business (2020-2025) & (US$ Million)
Table 120. Samsung Biologics Recent Development
Table 121. Sanofi(Vigil Neuroscience) Company Details
Table 122. Sanofi(Vigil Neuroscience) Business Overview
Table 123. Sanofi(Vigil Neuroscience) Neurodegenerative Disease CDMO Product
Table 124. Sanofi(Vigil Neuroscience) Revenue in Neurodegenerative Disease CDMO Business (2020-2025) & (US$ Million)
Table 125. Sanofi(Vigil Neuroscience) Recent Development
Table 126. Neurodegenerative Disease CDMO Market Trends
Table 127. Neurodegenerative Disease CDMO Market Drivers
Table 128. Neurodegenerative Disease CDMO Market Challenges
Table 129. Neurodegenerative Disease CDMO Market Restraints
Table 130. Research Programs/Design for This Report
Table 131. Key Data Information from Secondary Sources
Table 132. Key Data Information from Primary Sources
List of Figures
Figure 1. Neurodegenerative Disease CDMO Product Picture
Figure 2. Global Neurodegenerative Disease CDMO Market Share by Type: 2024 VS 2031
Figure 3. Small Molecule Drug CDMO Features
Figure 4. Biopharmaceutical CDMO Features
Figure 5. Cell and Gene Therapy (CGT) CDMO Features
Figure 6. OtherS Features
Figure 7. Global Neurodegenerative Disease CDMO Market Share by Application: 2024 VS 2031
Figure 8. Alzheimer's Disease
Figure 9. Parkinson's Disease
Figure 10. Huntington's Disease
Figure 11. Amyotrophic Lateral Sclerosis (ALS)
Figure 12. Multiple System Atrophy (MSA)
Figure 13. Progressive Supranuclear Palsy (PSP)
Figure 14. Others
Figure 15. Neurodegenerative Disease CDMO Report Years Considered
Figure 16. Global Neurodegenerative Disease CDMO Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 17. Global Neurodegenerative Disease CDMO Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 18. Global Neurodegenerative Disease CDMO Revenue Market Share by Region: 2020 VS 2024
Figure 19. North America Neurodegenerative Disease CDMO Revenue (US$ Million) Growth Rate (2020-2031)
Figure 20. Europe Neurodegenerative Disease CDMO Revenue (US$ Million) Growth Rate (2020-2031)
Figure 21. China Neurodegenerative Disease CDMO Revenue (US$ Million) Growth Rate (2020-2031)
Figure 22. Japan Neurodegenerative Disease CDMO Revenue (US$ Million) Growth Rate (2020-2031)
Figure 23. Southeast Asia Neurodegenerative Disease CDMO Revenue (US$ Million) Growth Rate (2020-2031)
Figure 24. India Neurodegenerative Disease CDMO Revenue (US$ Million) Growth Rate (2020-2031)
Figure 25. South America Neurodegenerative Disease CDMO Revenue (US$ Million) Growth Rate (2020-2031)
Figure 26. Middle East Neurodegenerative Disease CDMO Revenue (US$ Million) Growth Rate (2020-2031)
Figure 27. Global Neurodegenerative Disease CDMO Market Share by Players in 2024
Figure 28. Global Top Neurodegenerative Disease CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Disease CDMO as of 2024)
Figure 29. The Top 10 and 5 Players Market Share by Neurodegenerative Disease CDMO Revenue in 2024
Figure 30. North America Neurodegenerative Disease CDMO Market Share by Type (2020-2025)
Figure 31. North America Neurodegenerative Disease CDMO Market Share by Application (2020-2025)
Figure 32. Europe Neurodegenerative Disease CDMO Market Share by Type (2020-2025)
Figure 33. Europe Neurodegenerative Disease CDMO Market Share by Application (2020-2025)
Figure 34. China Neurodegenerative Disease CDMO Market Share by Type (2020-2025)
Figure 35. China Neurodegenerative Disease CDMO Market Share by Application (2020-2025)
Figure 36. Japan Neurodegenerative Disease CDMO Market Share by Type (2020-2025)
Figure 37. Japan Neurodegenerative Disease CDMO Market Share by Application (2020-2025)
Figure 38. Southeast Asia Neurodegenerative Disease CDMO Market Share by Type (2020-2025)
Figure 39. Southeast Asia Neurodegenerative Disease CDMO Market Share by Application (2020-2025)
Figure 40. India Neurodegenerative Disease CDMO Market Share by Type (2020-2025)
Figure 41. India Neurodegenerative Disease CDMO Market Share by Application (2020-2025)
Figure 42. AC Immune Revenue Growth Rate in Neurodegenerative Disease CDMO Business (2020-2025)
Figure 43. Alterity Therapeutics Revenue Growth Rate in Neurodegenerative Disease CDMO Business (2020-2025)
Figure 44. Biogen Revenue Growth Rate in Neurodegenerative Disease CDMO Business (2020-2025)
Figure 45. Charles River Laboratories Revenue Growth Rate in Neurodegenerative Disease CDMO Business (2020-2025)
Figure 46. Coave Therapeutics Revenue Growth Rate in Neurodegenerative Disease CDMO Business (2020-2025)
Figure 47. Sysmex Corp Revenue Growth Rate in Neurodegenerative Disease CDMO Business (2020-2025)
Figure 48. Donanemab Revenue Growth Rate in Neurodegenerative Disease CDMO Business (2020-2025)
Figure 49. Eisai Revenue Growth Rate in Neurodegenerative Disease CDMO Business (2020-2025)
Figure 50. Fujirebio Holdings Revenue Growth Rate in Neurodegenerative Disease CDMO Business (2020-2025)
Figure 51. GenSight Biologics Revenue Growth Rate in Neurodegenerative Disease CDMO Business (2020-2025)
Figure 52. Neuropore Therapies Revenue Growth Rate in Neurodegenerative Disease CDMO Business (2020-2025)
Figure 53. Nevrargenics Revenue Growth Rate in Neurodegenerative Disease CDMO Business (2020-2025)
Figure 54. PPD Revenue Growth Rate in Neurodegenerative Disease CDMO Business (2020-2025)
Figure 55. Samsung Biologics Revenue Growth Rate in Neurodegenerative Disease CDMO Business (2020-2025)
Figure 56. Sanofi(Vigil Neuroscience) Revenue Growth Rate in Neurodegenerative Disease CDMO Business (2020-2025)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed
KEY QUESTIONS ADDRESSED BY THE REPORT
What is the annual compound growth rate of the global Neurodegenerative Disease CDMO market size from 2025 to 2031?
The annual compound growth rate of the global Neurodegenerative Disease CDMO market is 6.9% 2025 to 2031.
What was the global market size of Neurodegenerative Disease CDMO in 2025?
Which companies rank high in the global Neurodegenerative Disease CDMO market?
What was the global market size of Neurodegenerative Disease CDMO in 2031?
Which region is expected to have the highest market share?
Related Reports
Global Neurodegenerative Disease CDMO Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Neurodegenerative Disease CDMO market is projected to grow from US$ 770 million in 2025 to US$ 1220 million by 2032, at a CAGR of 6.9% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published Date: 2026-03-12
Pages: 133
USD 4900.00
(Single User License)
Global Neurodegenerative Disease CDMO Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Neurodegenerative Disease CDMO market size was US$ 770 million in 2025 and is forecast to reach a readjusted size of US$ 1220 million by 2032 with a CAGR of 6.9% during the forecast period 2026-2032.
Published Date: 2026-03-12
Pages: 98
USD 4250.00
(Single User License)
Global Neurodegenerative Disease CDMO Market Research Report 2026
The global Neurodegenerative Disease CDMO market was valued at US$ 770 million in 2025 and is anticipated to reach US$ 1220 million by 2032, at a CAGR of 6.9% from 2026 to 2032.
Published Date: 2026-03-12
Pages: 112
USD 2900.00
(Single User License)
Neurodegenerative Disease CDMO - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Neurodegenerative Disease CDMO was estimated to be worth US$ 770 million in 2025 and is projected to reach US$ 1220 million, growing at a CAGR of 6.9% from 2026 to 2032.
Published Date: 2026-03-09
Pages: 110
USD 3950.00
(Single User License)
Neurodegenerative Disease CDMO - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Neurodegenerative Disease CDMO was estimated to be worth US$ 735 million in 2024 and is forecast to a readjusted size of US$ 1149 million by 2031 with a CAGR of 6.9% during the forecast period 2025-2031.
Published Date: 2025-07-11
Pages: 118
USD 3950.00
(Single User License)
Global Neurodegenerative Disease CDMO Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Neurodegenerative Disease CDMO market is projected to grow from US$ 735 million in 2024 to US$ 1149 million by 2031, at a CAGR of 6.9% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published Date: 2025-07-11
Pages: 140
USD 4900.00
(Single User License)
Global Neurodegenerative Disease CDMO Market Research Report 2025
The global market for Neurodegenerative Disease CDMO was valued at US$ 735 million in the year 2024 and is projected to reach a revised size of US$ 1149 million by 2031, growing at a CAGR of 6.9% during the forecast period.
Published Date: 2025-07-11
Pages: 86
USD 2900.00
(Single User License)
Global Neurodegenerative Disease CDMO Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Neurodegenerative Disease CDMO market is projected to grow from US$ 770 million in 2025 to US$ 1220 million by 2032, at a CAGR of 6.9% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published: 2026-03-12
Pages: 133
USD 4900.00 (Single User License)Global Neurodegenerative Disease CDMO Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Neurodegenerative Disease CDMO market size was US$ 770 million in 2025 and is forecast to reach a readjusted size of US$ 1220 million by 2032 with a CAGR of 6.9% during the forecast period 2026-2032.
Published: 2026-03-12
Pages: 98
USD 4250.00 (Single User License)Global Neurodegenerative Disease CDMO Market Research Report 2026
The global Neurodegenerative Disease CDMO market was valued at US$ 770 million in 2025 and is anticipated to reach US$ 1220 million by 2032, at a CAGR of 6.9% from 2026 to 2032.
Published: 2026-03-12
Pages: 112
USD 2900.00 (Single User License)Neurodegenerative Disease CDMO - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Neurodegenerative Disease CDMO was estimated to be worth US$ 770 million in 2025 and is projected to reach US$ 1220 million, growing at a CAGR of 6.9% from 2026 to 2032.
Published: 2026-03-09
Pages: 110
USD 3950.00 (Single User License)Neurodegenerative Disease CDMO - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Neurodegenerative Disease CDMO was estimated to be worth US$ 735 million in 2024 and is forecast to a readjusted size of US$ 1149 million by 2031 with a CAGR of 6.9% during the forecast period 2025-2031.
Published: 2025-07-11
Pages: 118
USD 3950.00 (Single User License)Global Neurodegenerative Disease CDMO Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Neurodegenerative Disease CDMO market is projected to grow from US$ 735 million in 2024 to US$ 1149 million by 2031, at a CAGR of 6.9% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published: 2025-07-11
Pages: 140
USD 4900.00 (Single User License)Global Neurodegenerative Disease CDMO Market Research Report 2025
The global market for Neurodegenerative Disease CDMO was valued at US$ 735 million in the year 2024 and is projected to reach a revised size of US$ 1149 million by 2031, growing at a CAGR of 6.9% during the forecast period.
Published: 2025-07-11
Pages: 86
USD 2900.00 (Single User License)
CHOOSE LICENSE TYPE
USD 4250.00
USD 6375.00
USD 8500.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
WHY THIS REPORT
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now